Evidence map›Paper›PMID 22748294›Full record

ArticleAmerican journal of surgery2012

Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.

Leonard Armstrong, Amanda Arrington, Joohee Han, Tatyana Gavrikova, Eric Brown, Masato Yamamoto, Selwyn M Vickers, Julia Davydova

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role of Adenoviruses in Cancer Therapy.Frontiers in oncology · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Leonard ArmstrongDepartment of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Amanda Arrington
Joohee Han
Tatyana Gavrikova
Eric Brown
Masato Yamamoto
Selwyn M Vickers
Julia Davydova
University of Minnesota · USUniversity of Alabama at Birmingham · US

Funding

UAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J · 2010 to 2014
$11.1M
The Center for Health Disparities Research, Engagement, and Training (CeHDRET)P60MD003422 · NIMHD · UNIVERSITY OF MINNESOTA · PI AHLUWALIA, JASJIT SINGH · 2009 to 2013
$6.1M
Virus adjunctive therapies for pancreatic cancerP20CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J. · 2003 to 2007
$4.6M
Enhanced CRAd for Pancreatic CancerR01CA094084 · NCI · UNIVERSITY OF MINNESOTA · PI YAMAMOTO, MASATO · 2002 to 2013
$2.7M
Surgical Oncology Research Training ProgramT32CA132715 · NCI · UNIVERSITY OF MINNESOTA · PI VICKERS, SELWYN M · 2008 to 2012
$912k
NCI NIH HHS P20 CA101955NCI NIH HHS P50 CA101955NCI NIH HHS P50CA101955NCI NIH HHS R01 CA094084NCI NIH HHS R01CA094084NCI NIH HHS T32 CA132715NCI NIH HHS T32CA132715NIMHD NIH HHS 1P60MD003422NIMHD NIH HHS P60 MD003422
6 · The paper itself

Abstract

backgroundOncolytic adenoviruses provide a promising alternative for cancer treatment. Recently, adjuvant interferon (IFN)-alfa has shown significant survival benefits for pancreatic cancer, yet was impeded by systemic toxicity. To circumvent these problems adenovirus with high-level targeted IFN-alfa expression can be generated.

methodsConditionally replicative adenoviruses (CRAds) with improved virulence and selectivity for pancreatic cancer were generated. The vectors were tested in vitro, in vivo, and in human pancreatic cancer and normal tissue specimens.

resultsAdenoviral death protein and fiber modifications significantly improved oncolysis. CRAds selectively replicated in vitro, in vivo and showed persistent spread in cancer xenografts. They showed high-level replication in human pancreatic cancer specimens, but not in normal tissues. Improved IFN-CRAd oncolytic efficiency was shown.

conclusionsOptimized cyclooxygenase-2 CRAds show highly favorable effects in vitro and in vivo. We report a pancreatic cancer-specific, highly virulent, IFN-expressing CRAd, and we believe that adenovirus-based IFN therapy offers a new treatment opportunity for pancreatic cancer patients.

Indexed as

AdenoviridaeAdenovirus E3 ProteinsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell Line, TumorCyclooxygenase 2FemaleGene Transfer TechniquesHumansInterferon-alphaMiceMice, NudeOncolytic VirotherapyPancreatic NeoplasmsVirus Replicationadenovirus death protein, AdenovirusAdenovirus E3 ProteinsBiomarkers, TumorCyclooxygenase 2Interferon-alpha

Identifiers

PMID22748294
PMCPMC3467355
OpenAlexW2103566767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.